CAJ | 학술논문

非诺贝特是过氧化物酶增殖物激活受体α(PPAR-α)激动剂,在临床上作为调脂药物被广泛使用.它能够降低甘油三酯水平,升高高密度脂蛋白胆固醇(HDL-C)水平,降低冠脉血管事件的风险.最近的临床试验表示,非诺贝特能够延缓增殖期糖尿病视网膜病变的进展,且发现非诺贝特的这种作用与其抗炎作用等有关.现主要就非诺贝特在糖尿病视网膜病变发病中的作用及其机制进行综述.
비낙패특시과양화물매증식물격활수체α(PPAR-α)격동제,재림상상작위조지약물피엄범사용.타능구강저감유삼지수평,승고고밀도지단백담고순(HDL-C)수평,강저관맥혈관사건적풍험.최근적림상시험표시,비낙패특능구연완증식기당뇨병시망막병변적진전,차발현비낙패특적저충작용여기항염작용등유관.현주요취비낙패특재당뇨병시망막병변발병중적작용급기궤제진행종술.
Fenofibrate,which is a peroxisome proliferator-activated receptor α (PPARα) agonist,has beneficial effects on lipid profiles that include lowering triglycerides and increasing high-density lipoprotein cholesterol,and reducing coronary vascular events in large clinical trials.Results from recent clinical trials suggest a role for fenofibrate in reducing the progression and/or inducing regression in mild-to-moderate nonproliferative diabetic retinopathy (DR).The role of fenofibrate in the pathogenesis of diabetic retinopathy is associated with its anti-inflammatory properties.The effect and mechanisms of fenofibrate in the pathogenesis of diabetic retinopathy are reviewed in this article.